Female External Catheter Market: as BD PureWick surpassing 50 million female unit disposals by August 2024 and BD FY2024 Urology and Critical Care revenue of USD 1,554 Million at 13.1% growth establish the commercial validation of non-invasive female external urinary collection as a scalable acute and long-term care modality, the Urology Care Foundation reporting 30 to 40% prevalence of female urinary incontinence among adult women creates the structural demand base sustaining disposable urine collection device adoption, so hospital CAUTI prevention protocols and the CDC May 2024 stroke data confirming 1 in 5 women between 55 and 75 suffer a stroke expand the post-acute and home care addressable market for the female external catheter category.

The global female external catheter market size was USD 519 Million in 2025 and is expected to register a revenue CAGR of 8.5% during the forecast period. Market revenue growth is driven by factors such as BD PureWick establishing the wick-based female external urinary collection category at hospital acute care scale, the Urology Care Foundation confirming 30 to 40% prevalence of female urinary incontinence among adult women as the structural demand base, and as well as the CDC May 2024 stroke incidence data confirming 1 in 5 women between 55 and 75 suffer a stroke creating a large post-acute bladder management patient population requiring non-invasive external urine collection alternatives to indwelling catheterisation. The first driving factor is BD PureWick surpassing 50 million female unit disposals by August 2024 per BD product documentation, and BD confirming in Q1 FY2024 that its female external urine collection market is a billion-dollar market growing double-digits, with BD FY2024 Urology and Critical Care segment revenue of USD 1,554 Million at 13.1% growth and BD FY2025 disclosing strong double-digit growth in the November 2025 press release, demonstrating the commercial scale and adoption trajectory of the wick-based female external catheter category at US hospital acute care and ICU settings. The second driving factor is the 30 to 40% prevalence of female urinary incontinence among adult women confirmed by the Urology Care Foundation, representing a structural epidemiological demand base of tens of millions of US women experiencing UI who represent the primary non-invasive external collection device target population at both hospital and home care settings. The third driving factor is the CDC May 2024 stroke surveillance data confirming that 1 in 5 women between 55 and 75 suffer a stroke, creating a large and growing post-acute stroke bladder management patient population requiring non-invasive urine collection management at hospital stroke units, rehabilitation facilities, and home care settings where indwelling catheterisation creates CAUTI risk and skin integrity complications that wick-based external female catheter systems avoid. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way hospital CAUTI prevention protocols increasingly recognise non-invasive external female urine collection as a clinically superior alternative to indwelling urethral catheterisation for female patients without urological indications requiring urethral catheter placement, which allows PureWick-format female external catheters to be specified in hospital-level CAUTI prevention policies that protect the device from cost-containment pressure by embedding it in a patient safety protocol rather than an optional supply choice. Once a hospital nursing unit adopts a CAUTI prevention protocol that specifies external female urinary collection as the preferred alternative to indwelling catheterisation for eligible female patients, every qualifying female patient admission generates a disposable female external catheter purchase order rather than a clinical utility decision made at bedside nursing discretion, so the external female catheter disposable revenue per hospital compounds with nursing unit census volume growth. As a result, demand and revenue share are concentrating around the wick-based female external catheter platforms with the broadest hospital CAUTI prevention protocol endorsement and the deepest hospital supply chain positioning, and the forecast tilts toward these protocol-embedded disposable platforms rather than cup-based or adhesive format alternatives competing on product specification alone. For instance, in April 2024, Medline became the exclusive US acute care distributor of Consure Medical's QiVi MEC female external catheter, one of several commercial events that shaped the female external catheter competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the commercial validation of the wick-based female external catheter category by BD PureWick's reaching 50 million female unit disposals by August 2024, demonstrating that non-invasive external female urine collection has achieved the clinical adoption scale at US hospital acute care and long-term care settings that transforms it from an emerging device category into a standard procurement item in hospital continence care supply chains. Commercial validation works as a demand driver because the 50 million unit milestone confirms that hospital nursing units at scale are incorporating wick-based external female catheter disposables into daily patient care protocols for urinary incontinence management and CAUTI prevention rather than reserving the product for isolated patient populations, creating the recurring daily disposable demand that sustains high double-digit annual revenue growth at BD UCC segment level. BD confirmed in Q1 FY2024 that its female external urine collection business represents a billion-dollar market growing double-digits, followed by BD FY2024 Urology and Critical Care segment revenue of USD 1,554 Million at 13.1% growth, and BD disclosing strong double-digit growth in the female external catheter business in the November 2025 press release for FY2025 results. The effect on the market is that BD's sustained double-digit revenue growth in the female external catheter category at a USD 1,554 Million-plus segment revenue base confirms that the market has entered the scaling phase of adoption rather than the early clinical introduction phase, which is why the 8.5% CAGR forecast reflects both the established BD PureWick revenue momentum and the growing competitive entry from Consure Medical, TillaCare, and Hollister into a validated and growing clinical market. These are some of the key factors driving revenue growth of the market.

The second driver is the structural epidemiological demand base of tens of millions of women experiencing urinary incontinence or requiring post-acute bladder management after stroke or surgery, creating a patient population whose clinical management need for non-invasive urine collection solutions is independent of technology innovation cycles and driven primarily by aging demographic trends and chronic disease prevalence. Epidemiological demand works commercially because the 30 to 40% prevalence of female urinary incontinence confirmed by the Urology Care Foundation means that a substantial proportion of every hospital inpatient female census and long-term care facility female resident population qualifies for female external catheter use as a CAUTI-safe alternative to indwelling catheterisation, creating non-discretionary daily disposable demand that compounds with facility census volume growth. The CDC May 2024 stroke surveillance data confirming that 1 in 5 women between 55 and 75 suffer a stroke creates a large and growing post-acute stroke bladder management patient population at hospital stroke units and rehabilitation facilities where neurogenic bladder dysfunction frequently accompanies stroke recovery and requires external urine collection management. In April 2024, Medline became the exclusive US acute care distributor of Consure Medical's QiVi MEC female external catheter system, expanding the competitive alternative to BD PureWick at hospital supply chain procurement committees and validating that the market is large enough to support multiple commercial female external catheter platforms. These are some of the key factors driving revenue growth of the market.

BD confirmed in Q1 FY2024 that its female external urine collection business represents a billion-dollar market growing double-digits. At 50 million female unit disposals by August 2024, BD PureWick has achieved the adoption scale that transforms non-invasive external female urine collection from an emerging device category into a standard CAUTI prevention protocol component at US hospital nursing units, generating recurring daily disposable demand that sustains high double-digit annual revenue growth at the BD Urology and Critical Care segment level.

The third driver is the progressive embedding of non-invasive external female urine collection in hospital CAUTI prevention protocols that specify it as the preferred catheter-free alternative for eligible female patients, because CAUTI prevention protocol compliance is a patient safety quality metric tracked by The Joint Commission and CMS value-based purchasing programmes, creating an institutional accountability structure that protects female external catheter procurement from discretionary cost-containment in the same way that regulatory compliance spending is protected. CAUTI prevention protocol demand works commercially because once a hospital nursing unit's CAUTI prevention protocol specifies external female urinary collection for patients meeting the specified clinical criteria, the nursing staff implements the protocol on every qualifying female patient admission without requiring per-patient clinical utility decision-making, so the per-nursing-unit female external catheter disposable demand is predictable from census volume rather than variable with individual nursing staff discretion. The CAUTI prevention protocol adoption trajectory is supported by CMS value-based purchasing metrics that penalise hospitals for catheter-associated urinary tract infection rates above the national benchmark, creating a financial incentive for hospital infection preventionists to drive CAUTI prevention protocol standardisation including female external catheter adoption across all nursing units treating female patients. In November 2025, BD FY2025 results confirmed strong double-digit growth in the female external catheter business, demonstrating the sustained commercial impact of CAUTI prevention protocol adoption across the US hospital nursing infrastructure. These are some of the key factors driving revenue growth of the market.

However, the female external catheter market faces adoption constraints from limited home care reimbursement coverage and product fit variability across diverse female anatomy. Because home care insurance coverage for female external catheters including Medicare Part B coverage determinations remain inconsistently defined, with many insurers classifying wick-based external female catheters as incontinence supplies subject to limited coverage caps rather than as urological devices eligible for standard DME reimbursement, the home care addressable market is constrained to out-of-pocket consumer purchase at retail and direct-to-consumer pricing levels that are substantially below the hospital disposable pricing that anchors the market revenue base. Product fit variability across diverse female anatomy is a second constraint, because wick-based external female catheters require careful positioning and anatomical contact to create effective urine collection without leakage, and patients with anatomical variations including labial redundancy, atrophic skin changes, or significant obesity may experience product seal failure that limits clinical reliability and drives nursing staff to revert to indwelling catheterisation rather than troubleshoot external catheter fit at high-census nursing units under time pressure. Clinical awareness gap among physicians regarding non-invasive female external catheter availability is the third constraint, as the absence of a male external catheter equivalent product category in the female patient population for most of medical history means that many physicians ordering urinary catheterisation for female patients default to indwelling catheter orders without considering the non-invasive external alternative, requiring patient safety team and infection preventionist education and intervention to drive protocol adoption at hospital nursing departments. These factors substantially limit female external catheter market growth over the forecast period.

Based on product, the global female external catheter market is segmented into wick-based female external catheters, cup-based female external catheters, and adhesive female external catheters. Wick-based female external catheters hold the largest revenue share at approximately 68%, dominated by BD PureWick across hospital acute care and long-term care settings with 50 million unit disposals by August 2024, and joined by Consure Medical QiVi MEC following the April 2024 Medline exclusive US acute care distribution agreement. Cup-based female external catheters are expected to register a rapid revenue growth rate in the global female external catheter market over the forecast period, driven by TillaCare and Hollister cup-based product launches targeting the home care and long-term care settings where wick-based products have lower clinical awareness and adoption.

Based on end-use, the global female external catheter market is segmented into hospitals and acute care units, long-term care and nursing facilities, and home care. Hospitals and acute care units hold the largest revenue share, anchored by BD PureWick hospital supply chain positioning and CAUTI prevention protocol adoption at hospital medical-surgical, ICU, and post-acute nursing units. Home care is expected to register the most rapid revenue growth rate in the global female external catheter market over the forecast period, driven by aging-in-place trends and the CDC stroke data confirming a large home care female urinary incontinence and post-stroke bladder management patient population, with TillaCare and direct-to-consumer female external catheter brands expanding distribution through pharmacy and e-commerce channels.

Based on regional analysis, the female external catheter market in North America accounted for largest revenue share in 2025 at approximately 62% of global revenue. The United States drives the regional position through BD PureWick's dominant US hospital supply chain positioning, the Urology Care Foundation's US clinical advocacy network for female urinary incontinence management, and CAUTI prevention programme adoption driven by CMS value-based purchasing metrics at US hospital nursing units. BD FY2024 Urology and Critical Care revenue of USD 1,554 Million at 13.1% growth reflects the US-anchored commercial momentum of the female external catheter category. The Iran-US sanctions and Strait of Hormuz disruption do not materially affect female external catheter supply chains, as PureWick manufacturing is concentrated in North American and European facilities outside the affected logistics corridors.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, France, and the Netherlands represent the four largest national female external catheter markets in Europe. European hospital continence care protocols are less advanced than US CAUTI prevention frameworks in specifying non-invasive external female collection as a standard alternative to indwelling catheterisation, creating a clinical awareness and protocol adoption gap that will need to close before European hospital demand approaches US per-bed penetration rates. Coloplast and ConvaTec, both European-headquartered continence care companies, are expanding their female external catheter product ranges to address European hospital and home care demand for non-invasive female urinary collection alternatives.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, Australia, and South Korea represent the four largest national female external catheter markets in the Asia Pacific region. Japan's aging female population and high hospital nursing standards create a favourable adoption environment for non-invasive external female catheter products at hospital long-stay ward and geriatric care settings. China's hospital infection prevention quality improvement initiatives at tier 1 and tier 2 city hospital networks are creating awareness of CAUTI prevention protocols that include female external catheterisation alternatives.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national female external catheter markets. Brazil's private hospital network in major urban centres is the primary adoption setting for premium female external catheter products including PureWick, while public hospital adoption is constrained by procurement budget limitations that prioritise lower-cost incontinence management alternatives.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets. GCC private hospital networks serving large female patient populations from multiple national backgrounds are beginning to adopt CAUTI prevention protocols that include non-invasive external female catheter alternatives, supported by Joint Commission International accreditation requirements for infection prevention protocol standardisation at accredited GCC hospital facilities.